NeuroMetrix, Inc. short interest in 2019
In 2019, NeuroMetrix, Inc.'s disclosed short interest ran from 4.33% of shares outstanding on 15 Jan 2019 to 0.91% on 15 Nov 2019, a change of -3.42 percentage points. The year's high was 4.33% on 15 Jan 2019 and its low 0.91% on 15 Nov 2019, averaging 2.42% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 4.84 days on 28 Feb 2019. Full history: NeuroMetrix, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024
2019 in figures
- Start of year
- 4.33% (15 Jan 2019)
- End of year
- 0.91% (15 Nov 2019)
- Change
- -3.42 pp
- High
- 4.33% (15 Jan 2019)
- Low
- 0.91% (15 Nov 2019)
- Average
- 2.42%
- Highest days to cover
- 4.84 (28 Feb 2019)
- SEC filings marked
- 8
Every report in 2019
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2019 | 4.33% | 1.86 | |
| 31 Jan 2019 | 3.17% | 1.32 | 10-K filed, results (8-K) |
| 15 Feb 2019 | 3.03% | 4.49 | |
| 28 Feb 2019 | 3.02% | 4.84 | |
| 15 Mar 2019 | 2.99% | 1.88 | |
| 29 Mar 2019 | 3.30% | 2.56 | |
| 15 Apr 2019 | 3.02% | 2.23 | |
| 30 Apr 2019 | 2.47% | 1.80 | 10-Q filed, results (8-K) |
| 15 May 2019 | 2.41% | 1.00 | |
| 31 May 2019 | 2.53% | 1.91 | |
| 14 Jun 2019 | 3.83% | 1.00 | |
| 28 Jun 2019 | 2.61% | 1.94 | |
| 15 Jul 2019 | 2.20% | 1.43 | |
| 31 Jul 2019 | 1.94% | 2.01 | 10-Q filed, results (8-K) |
| 15 Aug 2019 | 1.79% | 2.18 | |
| 30 Aug 2019 | 1.80% | 2.87 | |
| 13 Sep 2019 | 1.51% | 1.00 | |
| 30 Sep 2019 | 1.32% | 1.10 | |
| 15 Oct 2019 | 1.21% | 1.00 | |
| 31 Oct 2019 | 1.45% | 1.28 | 10-Q filed, results (8-K) |
| 15 Nov 2019 | 0.91% | 1.12 |
See also: NeuroMetrix, Inc.'s full history · most shorted US stocks of 2019 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.